Anemia of chronic diseases


Cite item

Full Text

Abstract

The anemia originating under infectious inflammatory processes, non-infectious inflammatory diseases, tumors is called “anemia under chronic diseases” to emphasize the role of main disease in its pathogenesis. The rate of occurrence of anemia under certain diseases reaches 100%. But, in these situations, for all that diversity of pathogenic mechanisms of anemia, one of the main mechanisms is considered the redistribution of iron into cells of macrophage system activating under various inflammatory (infectious and non-infectious) or neoplastic processes. The anemia under chronic diseases by their prevalence takes second place after iron-deficiency anemia. The prevalence of anemia under chronic diseases in old and senile age varies from 2.9% to 61% in males and from 3.3% to 41% in females. In young and mature age, anemia under chronic diseases is more often detected in females. In hospitalized patients of old age its rate goes up to 36-80% whereas in out-patients it goes to5-14%. Among patients with systemic diseases of connective tissue anemia occurs almost in half of patients and at that anemia under chronic diseases is prevailing. The diagnostic criteria of anemia under chronic diseases are indicated in details. The main mode of correction of anemia in this category of patients is the treatment of active inflammatory process. This treatment includes antibacterial therapy considering character of supposed of verified infection agent, basic and antiinflammatory therapy of rheumatoid diseases, surgery treatment under corresponding indications (abscess of abdominal cavity, purulent pyelonephritis, etc.). In these situations, prescription of iron preparations, vitamin B12 as usually is inefficient and only delaying timely detection of main cause of anemia and onset of corresponding therapy. The picking out of anemia under chronic diseases as a separate pathogenic alternative and awareness about it both have important value in view of matching of this alternative to iron-deficiency anemia and certain sideroblastic anemias although essence and therapeutic approaches under these anemias are different.

About the authors

Nail' Aleksandrovich Andreitchev

The Kazan state medical university

Email: nail_andre@mail.ru
Кафедра факультетской терапии и кардиологии

Larisa Vasil'evna Baleyeva

The Kazan state medical university

Email: smir151@rambler.ru
Кафедра факультетской терапии и кардиологии

References

  1. Bauer J.H., Reams G.P. The angiotensin II type 1 receptor antagonists. A new class of antihypertensive drugs. Arch. Intern. Med. 1995; 155 (13): 1361-8.
  2. Чазова И.Е., Фомин В.В., Пальцева Е.М. Прямой ингибитор ренина алискирен: новые возможности защиты почек при артериальной гипертонии. Клиническая нефрология. 2009; 1: 44-9.
  3. Чазова И.Е., Фомин В.В. Прямой ингибитор ренина алискирен: возможности коррекции кардио-ренального синдрома. Системные гипертензии. 2009; 4: 53-8.
  4. Диагностика и лечение артериальной гипертензии: Российские рекомендации. Системные гипертензии. 2010; 3: 5-26.
  5. Демидова А.В. Анемии. М.: МЕДпресс-информ. 2006.
  6. Клинические рекомендации. Стандарты ведения больных. Вып. 2. М.: ГЭОТАР-Медиа, 2008
  7. Cash J.M., Slars D.A. The anemia of chronic disease: spectrum of associated diseases in series of unselected hospitalized patients. Am. J. Med. 1989; 87.
  8. Ковалева Л.Г. Анемия у пожилых. Врач. 2005; 1: 15-9.
  9. Окороков А.Н. Диагностика болезней внутренних органов. т. 4. Диагностика болезней системы крови. М.: Медицинская литература. 2001.
  10. Murphy S.T., Parfrey P.S. The impact of anemia correction on cardiovascular disease in end-stage renal disease. Semin. Nephrol. 2000; 20: 350-5.
  11. Милованов Ю.С., Милоанова С.Ю. Анемия при диабетической нефропатии. Лечащий врач. 2008; 3: 20-4.
  12. Ермоленко В.М., Хасабов Н.Н., Михайлова Н.А. Рекомендации по применению препаратов железа у больных с хронической почечной недостаточностью. Анемия. 2005; 2: 9-25.
  13. Луговская С.А., Морозова В.Т., Почтарь М.Е. и др. Лабораторная гематология. М.: Юнимед-пресс; 2002.
  14. Меньшиков В.В., ред. Методики клинических лабораторных исследований. М.: Лабора; 2008.
  15. Volberding P.A., Levine A.M., Dieterich D. Anemia in HIV Working Group. Anemia in HIV infection: clinical impact and evidence-based management strategies. Clin. Infect. Dis. 2004; 38: 1454-63.
  16. NKF-K/DOQI (National Kidney Foundation/Kidney Disease Outcomes Quality Initiative, 2002) Clinical Practice Guidelines for anemia of chronic kidney disease: update 2000. Am. J. Kidney Dis. 2001; 37 (Suppl. 1): 182-238.
  17. Weiss G. Pathogenesis and treatment of anemia of chronic disease. Blood Rev. 2002; 6: 87-96.
  18. Чучалин А.Г., ред. Российский терапевтический справочник. М.: ГЭОТАР-Медиа. 2007.
  19. Андерсон Ш. Атлас гематологии. Пер. с англ. М.: Логосфера; 2007.
  20. Павлов А.Д., Морщакова Е.Ф. Этиология и патогенез анемий при злокачественных новообразованиях. Вопросы гематологии, онкологии и иммунологии в педиатрии. 2004; 3 (1): 50-5.
  21. Арутюнов Г.П. Анемия у больных с ХСН. Сердечная недостаточность. 2003; 4 (5): 224-8.
  22. Андреичев Н.А., Балеева Л.В. Железодефицитные состояния и железодефицитная анемия. Вестник современной клинической медицины. 2009; 2 (3): 60-5.
  23. Бокарев И.Н., Немчинов Е.Н., Кондратьева Т.Б. Анемический синдром. М.: Практическая медицина. 2006.

Copyright (c) 2014 Eco-Vector


 


This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies